Brainomix Ltd. raised £14 million ($18 million) in a series C financing round to expand its AI-powered imaging solution, Brainomix 360 Stroke, into the U.S. market. Funds will also go towards advancing the Brainomix 360 E-Lung, which can accurately predict the progression of lung fibrosis. “This series C round is a vital fundraise for us,” Michalis Papadakis, CEO and co-founder of Brainomix, told BioWorld. “We are in a growth stage where we want to bring this next generation of stroke AI into the U.S. market.”

Brain.space Ltd. raised $11 million in a series A funding round for its technologies which uses brain data and AI to understand and predict human behavior. The round was led by Toyota Ventures, with significant participation from Mangrove Capital Partners and The Group Ventures. The funding included a $3.5 million non-dilutive grant from the Israel Innovation Authority.